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Abstract
Background: Gastrointestinal irritability can deter pregnant women from starting or continuing
prenatal multivitamin supplementation. In a previous study, suboptimal tolerability was observed
among pregnant women taking a large tablet (18 mm × 8 mm × 8 mm) multivitamin with high
elemental iron content (60 mg as ferrous fumarate). The objective of the present study was to
compare rates of adherence and reported adverse events among pregnant women who were
randomized to commence supplementation with a small-tablet prenatal multivitamin, containing
either low or high iron content.
Methods:  Pregnant women who called the Motherisk Program (Hospital for Sick Children,
Toronto) and had not started taking or had discontinued any multivitamin due to adverse events
were included in this prospective, randomized, open-label, 2-arm study. Women were randomized
to take a small-size (16 mm × 9 mm × 4 mm), low elemental iron content (35 mg as ferrous
fumarate) multivitamin ('35 mg' group); or a small-size (5 mm radius, 5 mm thickness), high
elemental iron content (60 mg as ferrous sulphate) multivitamin ('60 mg' group). Follow-up
interviews documented pill intake and adverse events. Rates of adherence and adverse events were
compared between groups using chi-squared tests and Kaplan-Meier survival curves.
Results: Of 167 randomized women, 92 in the '35 mg' group and 75 in the '60 mg' group were
included in the analysis. Despite ideal conditions and regular follow-ups, mean adherence based on
pill intake recall, in both groups was approximately 50%. No statistically significant difference was
detected in proportions of women who actually started taking either multivitamin. Among those
who started, no difference was detected in rates of adherence or reported adverse events.
Conclusion:  The present results suggest that iron content is not a major determinant of
adherence to prenatal multivitamins. Combined with our previous study, tablet size may be the
more definitive factor affecting adherence.
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Background
Multivitamin-mineral supplementation is recommended
before and during pregnancy to ensure adequate intake of
several key nutrients including folate, iron, and more
recently vitamin D – all of which have importance among
pregnant women, women of childbearing age, and during
fetal development [1-6]. Folic acid supplementation has
been well documented to reduce the risk of neural tube
defects (i.e. spina bifida) [7-9], and emerging evidence
suggests that folic acid-containing multivitamin supple-
ments are associated with reducing the risk of other mal-
formations and certain pediatric cancers [10-13].
Furthermore, as pregnancy progresses, body size
increases, alongside the nutritional requirements of the
developing fetus, resulting in continuous depletion of
vitamins and minerals that diet alone may not replenish
[14,15]. Thus, multivitamin-mineral supplementation is
considered necessary.
Most commonly used prenatal multivitamins contain a
high iron dose (i.e. 60 mg elemental iron) and are large in
tablet size. Pregnant women may experience gastrointesti-
nal (GI) symptoms, particularly 'morning sickness', aggra-
vated by the iron content or swallowing a large tablet
[16,17]. Approximately 80% of pregnant women experi-
ence some degree of nausea and vomiting of pregnancy
(NVP) which may improve towards the end of the first tri-
mester; however, it is not uncommon for symptoms to
continue beyond the first trimester or until the end of
pregnancy [17,18]. Pregnant women may also experience
heartburn, acid reflux, indigestion, constipation, or
diarrhea, and some women may experience exacerbation
of GI conditions such as irritable bowel syndrome (IBS),
Crohn's disease, or ulcerative colitis. The consequence of
GI irritability can deter pregnant women from starting or
continuing to take prenatal multivitamins.
In a previously published study, we determined that a
twice-daily, small-tablet prenatal multivitamin with a low
iron dose had better tolerability than a once-daily, large-
tablet prenatal multivitamin with a high iron dose [19]. It
would be of interest to assess the tolerability between 2
small-size prenatal multivitamins, differing in iron con-
tent. The objective of the present study was to compare
rates of adherence and reported adverse events among
pregnant women who were randomized to commence
supplementation with a small-tablet prenatal multivita-
min, containing either a low iron dose or high iron dose.
Methods
Inclusion and exclusion criteria for study subjects
Women who called the Motherisk Program at The Hospi-
tal for Sick Children in Toronto were included if they were
pregnant at the time of the call and had discontinued or
had not started any multivitamin due to adverse events
such as nausea, vomiting, constipation, diarrhea, heart-
burn, acid reflux, indigestion, or other GI irritability.
Motherisk is a counseling program that provides informa-
tion to women on the safety or risk to a developing fetus
and newborn of maternal exposure to drugs, chemicals,
and disease. Women were not included if their pregnancy
had progressed beyond 20 weeks gestation. Women were
to be excluded if they had hypersensitivities to any of the
ingredients available in any of the two multivitamin for-
mulations (either PregVit®, Duchesnay, Laval, Quebec; or
Orifer F®, Sanofi-Aventis, Laval, Quebec), if they had
hemochromatosis, hemosiderosis, or hemolytic anemia,
or if they did not consent to the study protocol. However,
no woman who was considered for the study was
excluded for these reasons.
Selection of prenatal multivitamins for study comparison
PregVit® is a prenatal multivitamin that contains 35 mg
elemental iron, as ferrous fumarate. The multiple vitamins
and minerals are formulated into 2 small tablets (one tab-
let: 16 mm × 9 mm × 4 mm), thus PregVit® is taken as 2
tablets per day. The 2 tablets contain different vitamins
and minerals, particularly separating the iron (morning
tablet) from the calcium (evening tablet) to optimize iron
absorption. The use of PregVit® requires a physician's pre-
scription. Since Materna®  (Wyeth Pharmaceuticals,
Markham, Ontario; one tablet: 18 mm × 8 mm × 8 mm;
contained 60 mg elemental iron as ferrous fumarate at the
time of the study) or other generic products are the most
commonly used non-prescription (i.e. over-the-counter)
prenatal multivitamins, they were not selected for com-
parison in the study because enrolled subjects who had
discontinued a prenatal multivitamin most likely had dis-
continued any one of them. Ethically, subjects in this sit-
uation cannot be randomized to resume Materna®  or
another generic prenatal multivitamin.
Instead, Orifer F® was selected as the small-tablet (one tab-
let: 5 mm radius, 5 mm thickness) prenatal multivitamin,
containing a high iron content (60 mg elemental iron as
ferrous sulphate). It is taken daily as a single tablet and the
use of Orifer F® does not require a physician's prescription
(i.e. over-the-counter). Comparing PregVit® to Orifer F®
would address separation of the potential effect of iron
content from that of tablet size on multivitamin tolerabil-
ity among pregnant women.
Subject recruitment and data collection
Between October 2004 and October 2006, women who
called either the Motherisk General Information line or
the Motherisk Nausea and Vomiting of Pregnancy (NVP)
Helpline were introduced to the study by a Motherisk
counselor, based on the inclusion and exclusion criteria.
If the caller was interested in study participation, the
counselor referred the caller to the research coordinator.BMC Pregnancy and Childbirth 2008, 8:17 http://www.biomedcentral.com/1471-2393/8/17
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The research coordinator explained the study and pro-
ceeded with enrolment after obtaining oral consent.
Based on a computer-generated randomization table,
women were randomized to one of two groups. Women
randomized to the '35 mg' group would commence sup-
plementation with PregVit® (low iron content, small size),
and women randomized to the '60 mg' group would com-
mence supplementation with Orifer F® (high iron content,
small size). An information package was mailed to each
woman, instructing her to commence supplementation
with her assigned prenatal multivitamin, according to the
product's standard dosing (twice daily for '35 mg' group,
once daily for '60 mg' group). Subjects were responsible
for obtaining their own multivitamin supply through
their health care providers. Information regarding the
study was faxed to the physician or other health care pro-
vider of each subject.
After enrolment, subjects received a one-week follow-up
telephone call and then were interviewed by telephone on
a monthly basis until the end of pregnancy. Each inter-
view documented obstetrical and medical information,
adherence based on pill intake recall, and any reported
adverse events. Discontinuation of the assigned multivita-
min was defined as intentionally not taking the supple-
ment and most likely not resuming the supplement. The
date(s) of discontinuation at any time(s) during study
participation was documented as the date(s) reported by
the subject during a monthly interview.
Study completion was defined as completing monthly tel-
ephone interviews (when possible) to document pill
intake and adverse events up until the end of pregnancy
(i.e. 36 weeks gestation or further). Overall adherence was
defined as the percentage of pill intake out of the pre-
scribed (i.e. she ingested 200 of the 300 prescribed pills,
thus her overall adherence was 67%). Standard adherence
was defined as pill intake (out of the prescribed) of at least
80% (i.e. woman A ingested 82% of her pills, thus she
adhered to the study intervention, while woman B
ingested 67% of her pills, thus she was not adherent to
study intervention). Prenatal multivitamins are intended
for daily consumption during pregnancy, thus the
number of pills prescribed was defined as the expected
number of pills to be consumed for the assigned multivi-
tamin for the time of study participation. For example,
women in the '35 mg' group were prescribed 2 tablets per
day and in a month of 30 days, were expected to take 60
tablets, while women in the '60 mg' group (although the
multivitamin was non-prescription) would be expected to
take 30 tablets for that same month. The study was
approved by the Research Ethics Board of the Hospital for
Sick Children, and all subjects gave oral, informed con-
sent.
Data analysis
Rates of adherence and adverse events were compared
using chi-squared tests, as appropriate. Adherence was
Rates of adherence between 2 prenatal multivitamin groups,  represented as Kaplan-Meier survival curves and based on  the proportion of subjects with standard adherence (80% or  greater pill intake), once supplementation commenced Figure 2
Rates of adherence between 2 prenatal multivitamin 
groups, represented as Kaplan-Meier survival curves 
and based on the proportion of subjects with stand-
ard adherence (80% or greater pill intake), once sup-
plementation commenced. (Black solid line) 35 mg iron 
group, n = 57. (Black broken line) 60 mg iron group, n = 47.
Enrolled subjects and data collected Figure 1
Enrolled subjects and data collected. Total no. of sub-
jects who completed the study, n = 140. Total no. of subjects 
with (complete or partial) data collected for study, n = 158.BMC Pregnancy and Childbirth 2008, 8:17 http://www.biomedcentral.com/1471-2393/8/17
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also compared between the 2 treatment groups through
Kaplan-Meier survival curves in 2 ways. The first survival
curve analysis compared the proportion of women with
standard adherence (i.e. at least 80% pill intake over
time), after having commenced supplementation with the
assigned multivitamin, and the p-value was determined
by the Wilcoxon (Peto-Prentice) test. The second survival
curve analysis compared overall adherence among
women who commenced supplementation with the
assigned multivitamin, at any percentage of pill intake
over time, and the p-value was determined by the log rank
statistic. All curves were plotted from the coordinates of
100% (y-axis point of 1.0) at time zero (x-axis point of 0)
to represent that at the beginning of the study, all subjects
who commenced supplementation in each multivitamin
group were adherent. Instead of fatality as the event which
causes the curves to decline (as commonly used in sur-
vival curve analysis), the events were modified for the
present analyses and defined as the following: a) standard
adherence (i.e. at least 80% pill intake) not achieved once
supplementation was initiated (first survival curve analy-
sis), and b) discontinuation of assigned multivitamin
after having commenced supplementation, at any per-
centage of pill intake (second survival curve analysis).
Results
Between October 2004 and October 2006, 167 pregnant
women were enrolled into the study through the Mother-
isk Program (Hospital for Sick Children), 92 women were
randomized to the '35 mg' group (PregVit®), and 75
women were randomized to the '60 mg' group (Orifer F®).
Although 27 women did not complete the study for vari-
ous reasons (i.e. miscarriage, lost contact), some data were
still collected and included in the analysis (Figure 1).
Based on the inclusion criteria, 67% of subjects were
enrolled because they had discontinued a previous multi-
vitamin supplement in the current pregnancy, and the
most frequently reported reasons for discontinuing or not
starting to take any multivitamins were NVP (78%), tablet
size or swallowing difficulties (32%), and various GI
symptoms (Table 1). There was a noticeable difference
between the 2 groups in terms of tablet size and constipa-
tion as the reasons reported for non-adherence to any pre-
vious multivitamins (Table 1). However, 66% of subjects
Table 1: Subject characteristics at time of enrolment
Prenatal multivitamin groups, differing in iron content
60 mg iron group n = 75 35 mg iron group n = 92 Total N = 167
Study inclusion:
a) Had not started multivitamin in current pregnancy 27 (36%) 28 (30%) 55 (33%)
b) Had discontinued multivitamin in current pregnancy 48 (64%) 64 (70%) 112 (67%)
Reasons for (a) or (b):
Nausea and/or vomiting (NVP) 62 (83%) 68 (74%) 130 (78%)
Tablet sizeψ, swallowing difficulties, other tablet properties (i.e. taste, smell) 33 (44%) 20 (22%) 53 (32%)
Constipationβ 4 (5%) 14 (15%) 18 (11%)
Abdominal pain, GI irritability, diarrhea, heartburn, reflux 10 (13%) 13 (14%) 23 (14%)
GI medical condition (i.e. IBS, Crohn's disease) 2 (3%) 2 (2%) 4 (2%)
Doctor's advice, not supplement taker, or lacked information 5 (7%) 6 (7%) 11 (7%)
Maternal age (years)
Mean ± standard deviation
30 ± 5 31 ± 5 31 ± 5
Gravidity:
First pregnancy 23 (31%) 20 (22%) 43 (26%)
Second or higher pregnancy 52 (69%) 72 (78%) 124 (74%)
Multivitamin intake in a previous pregnancy* 45/52 (87%) 59/72 (82%) 104/124 (84%)
Discontinued multivitamin in a previous pregnancy* 26/45 (58%) 28/59 (47%) 54/104 (52%)
*Data missing for 1 subject.
ψ For the subjects who reported issues with tablet size as the reason for non-adherence with previous multivitamins, 22/33 (66%) in the '60 mg' 
group and 13/20 (65%) in the '35 mg' group still commenced supplementation with the assigned multivitamins.
β For the subjects who reported constipation as the reason for non-adherence with previous multivitamins, 2/4 (50%) in the '60 mg' group and 12/
14 (86%) in the '35 mg' group still commenced supplementation with the assigned multivitamins.BMC Pregnancy and Childbirth 2008, 8:17 http://www.biomedcentral.com/1471-2393/8/17
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in the '60 mg' group who reported issues with tablet size
as a reason for prior non-adherence, still commenced sup-
plementation with the assigned multivitamin, similarly to
the 65% of subjects in the '35 mg' group who also
reported prior issues with tablet size yet still commenced
supplementation with the assigned multivitamin. As for
the differences in previously reported constipation, it also
had minimal deterrence considering that 12 of the 14 sub-
jects (86%) in the '35 mg' group, who reported constipa-
tion as the reason for prior non-adherence, still
commenced supplementation with the assigned multivi-
tamin.
Eighty-four percent of subjects who were pregnant in the
past had also supplemented with multivitamins in a pre-
vious pregnancy, and 52% of these multivitamin-takers
had also discontinued the supplements in a previous
pregnancy (Table 1).
A similar proportion of women in both treatment groups
commenced supplementation with the assigned multivi-
tamin (73% of '35 mg' group and 76% of '60 mg' group)
(Table 2). There was no difference between the 2 groups
in the gestational age at which subjects started taking the
assigned multivitamins (gestational age as a mean with
standard deviation, 15 ± 6 weeks for the '35 mg' group, 16
± 7 weeks for the '60 mg' group, p = 0.57). Among those
who started, only 37–38% of both groups were adherent
at 80% or greater pill intake, and a slightly larger propor-
tion of both groups had a pill intake of 50% or greater
(Table 2). The range of pill intake for both groups was
zero to 100%, and the mean pill intake for both groups
was approximately 50%. Thus, no significant differences
were detected, and any partial data collected from subjects
who did not complete the study did not significantly
impact results. Similarly, a large proportion of women
with NVP in both groups commenced supplementation
with the randomly assigned multivitamins; however, the
proportions of NVP women who continued supplementa-
tion at 80% or greater pill intake was substantially lower
(Table 3), with no significant difference detected between
groups. Kaplan-Meier survival curves demonstrated no
significant differences between the 2 groups in adherence
over time, in terms of the proportion of women with
standard adherence, and thus, a pill intake of at least 80%
(Figure 2, p = 0.14) and in terms of the proportion of
women who continued, after having commenced, supple-
mentation with the randomly assigned multivitamin
(overall adherence) (Figure 3, p = 0.59).
There were no substantial differences in rates of reported
adverse events between the 2 groups, among the pregnant
women who commenced supplementation with the
assigned multivitamins (Table 4).
Discussion
Pregnant women enrolled in the present study were those
who contacted the Motherisk counseling program
(Toronto, Canada), thus they were probably self-selected
by heightened awareness of pregnancy health issues.
Sixty-seven percent of the enrolled women had also dis-
continued previous multivitamin supplements in the cur-
rent pregnancy due to various GI irritabilities, thus poor
adherence and GI adverse events were already established
among most women in the study. Although we examined
a selective group of pregnant women, the findings from
this present study may still be applied to a large propor-
tion of pregnant women in the general population, con-
sidering that approximately 80% of pregnant women
experience some degree of NVP or GI irritability and that
prenatal multivitamin supplementation is commonly rec-
ommended in pregnancy despite these potential chal-
lenges.
The limited sample size and unequal randomization of
the study is a reflection of recruiting and randomizing
subjects belonging to a vulnerable population. However,
the proportion of subjects who did not complete the study
(i.e. drop-out) did not differ between the 2 treatment
groups (15% for '35 mg' group, 17% for '60 mg' group).
Results from this randomized, prospective study of preg-
nant women who had not started or had discontinued
previous multivitamins due to adverse events suggested
that a prenatal multivitamin with a low iron dose did not
Rates of adherence between 2 prenatal multivitamin groups,  represented as Kaplan-Meier survival curves and based on  the proportion of subjects who commenced and continued  supplementation with assigned multivitamin (at any percent- age of pill intake) Figure 3
Rates of adherence between 2 prenatal multivitamin 
groups, represented as Kaplan-Meier survival curves 
and based on the proportion of subjects who com-
menced and continued supplementation with 
assigned multivitamin (at any percentage of pill 
intake). (Black solid line) 35 mg iron group, n = 57. (Black 
broken line) 60 mg iron group, n = 47.BMC Pregnancy and Childbirth 2008, 8:17 http://www.biomedcentral.com/1471-2393/8/17
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improve adherence as there was no significant difference
between the '35 mg' and '60 mg' groups. Although a large
proportion of women in both groups commenced supple-
mentation with the assigned multivitamins, a substan-
tially reduced proportion of women in both groups were
adherent throughout pregnancy (Tables 2). A major find-
ing of our study was that under ideal conditions of high
level of motivation and continued supervision, adherence
ranged from zero to 100%, and on average women con-
sumed only half of their pills in both groups.
Although recall of pill intake may be associated with
biased reporting as it generally results in over-estimation
of adherence; the interviewer encouraged subjects to be
honest and emphasized that no personal judgment was
placed on responses. Self-report has been commonly uti-
lized in several studies examining intervention adherence
[20-22].
Our results suggested that the low iron dose did not
reduce rates of GI adverse events; however, it is important
to acknowledge that the 2 multivitamin tablets differed in
a number of ways – volume, shape, iron compound, and
regimen – in addition to iron dose which were also con-
sidered when comparing the 2 multivitamins in terms of
both adherence and GI adverse events. Both prenatal mul-
tivitamins were small tablets (relative to other common
multivitamin tablet sizes), and although the shapes and
volumes of the tablets differed, it did not substantially
impact the issue of swallowing difficulties between the 2
groups (Table 4), and thus, no further significant differ-
ences were detected in adherence or other adverse events
between the 2 groups. These results suggest that tablet size
tolerability may reflect a relative perception of small tab-
lets versus large tablets, regardless of exact volume and
shape. As for the difference in iron preparations (35 mg as
ferrous fumarate and 60 mg as ferrous sulphate), it also
had a negligible impact as no significant differences were
detected in adherence or GI adverse events between the 2
groups, which is consistent with several studies that exam-
ined GI intolerance with respect to iron content (i.e.
doses, compounds) [16,23-25].
It is of interest that with the '35 mg' group, the prenatal
multivitamin is taken as 2 tablets per day, separating the
iron from calcium and hence preventing their interaction,
and allowing a lower dose of elemental iron (35 mg) to
yield similar systemic exposure as 60 mg taken with cal-
cium [26]. Despite having to take 2 tablets per day, overall
adherence with the '35 mg' group was not lower com-
pared to the once-per-day '60 mg' group. This finding is
consistent with the results of a systematic review showing
no differences in adherence between once versus twice
daily administration, with a significant decrease in adher-
ence only with three doses per day [27].
Multivitamin tolerability depends not only on the supple-
ment itself, but also on whether or not pregnant women
suffer from and properly manage NVP symptoms. Similar
to the general population of pregnant women, most of the
Table 3: Rates of adherence between 2 prenatal multivitamin groups, among subjects with nausea and vomiting of pregnancy (NVP) 
and study completionβ
Prenatal multivitamin groups, differing in iron content
35 mg iron group (n = 78) 60 mg iron group (n = 62) p-value (chi-squared test)
No. of subjects with NVP (at time of enrolment) 67 (86%) 56 (90%) 0.59
Proportion who started taking assigned prenatal multivitamin 49/67 (73%) 44/56 (79%) 0.63
Proportion who were ≥ 80% adherent.ψ 17/49 (35%) 18/44 (41%) 0.69
βNo significant difference was detected when partial data from subjects who did not complete the study were included.
ψ Based on at least 80% pill intake
Table 2: Rates of adherence between 2 prenatal multivitamin groups, based on subjects who completed the studyβ
Prenatal multivitamin groups, differing in iron content
35 mg iron group (n = 78) 60 mg iron group (n = 62) p-value (chi-squared test)
No. who started taking assigned prenatal multivitamin 57 (73%) 47 (76%) 0.86
Proportion who were ≥ 80% adherent†. 21/57 (37%) 18/47 (38%) 0.96
Proportion who were ≥ 50% adherent¶. 32/57 (56%) 28/47 (60%) 0.88
β No significant difference was detected when partial data from subjects who did not complete the study were included.
† Based on at least 80% pill intake.
¶ Based on at least 50% pill intakeBMC Pregnancy and Childbirth 2008, 8:17 http://www.biomedcentral.com/1471-2393/8/17
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pregnant women in both treatment groups experienced
NVP and this may well explain why overall adherence
under optimal conditions was not predominantly higher
than 50% pill intake.
Conclusion
These new findings must be considered when planning
public health strategies to ensure folate and other vitamin
and mineral supplementation throughout pregnancy. If
prenatal multivitamin formulation remains in the present
state, adherence among pregnant women, even with opti-
mal motivation and guidance, may not significantly
improve above 50% pill intake; however, this present
study demonstrated that potential improvements may be
associated with tablet size.
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*Only subjects who completed the study, with no significant difference detected when partial data from subjects who did not complete the study 
were included.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Pregnancy and Childbirth 2008, 8:17 http://www.biomedcentral.com/1471-2393/8/17
Page 8 of 8
(page number not for citation purposes)
14. Little BB: Pharmacokinetics during pregnancy: evidence-
based maternal dose formulation.  Obstetrics and Gynecology
1999, 93:858-68.
15. Stevenson AM: Pharmacokinetics in pregnant women and chil-
dren. MCN American.  Journal of Maternal Child Nursing 1998,
23:157.
16. Melamed N, Ben-Haroush A, Kaplan B, Yogev Y: Iron supplemen-
tation in pregnancy-does the preparation matter?  Arch Gyne-
col Obstet 2007, 276(6):601-4.
17. Nguyen P, Einarson A: Managing nausea and vomiting of preg-
nancy with pharmacological and non-pharmacological treat-
ments. [In Future Medicine].  Women's Health 2006, 2:753-60.
18. Lacroix R, Eason E, Melzack R: Nausea and vomiting during preg-
nancy: a prospective study of its frequency, intensity and pat-
terns of change.  American Journal of Obstetrics and Gynecology 2000,
182:931-7.
19. Ahn E, Pairaudeau N, Pairaudeau N Jr, Cerat Y, Couturier B, Fortier
A, Paradis E, Koren G: A randomized cross over trial of tolera-
bility and adherence of a micronutrient supplement with low
iron separated from calcium vs. high iron combined with cal-
cium in pregnant women.  BMC Pregnancy and Childbirth 2006,
6:10.
20. Giordano TP, Guzman D, Clark R, Charlebois ED, Bangsberg DR:
Measuring adherence to antiretroviral therapy in a diverse
population using a visual analogue scale.  HIV Clinical Trials 2004,
5(2):74-79.
21. Choo PW, Rand CS, Inui TS, Lee ML, Cain E, Cordeiro-Breault M,
Canning C, Platt R: Validation of patient reports, automated
pharmacy records, and pill counts with electronic monitor-
ing of adherence to antihypertensive therapy.  Medical Care
1999, 37(9):846-57.
22. Velligan DI, Lam YW, Glahn DC, Barrett JA, Maples NJ, Ereshefsky L,
Miller AL: Defining and assessing adherence to oral antipsy-
chotics: a review of the literature.  Schizophrenia Bulletin 2006,
32(4):724-742.
23. Kerr DNS, Davidson S: The prophylaxis of iron-deficiency ane-
mia in pregnancy.  Lancet 1958, 272:483-8.
24. Kerr DNS, Davidson S: Gastrointestinal intolerance to oral iron
preparations.  Lancet 1958, 272:489-92.
25. Milman N, Byg KE, Bergholt T, Erikson L: Side effects of oral iron
prophylaxis in pregnancy: a myth or reality?  Acta Haematol
2006, 115:53-7.
26. Ahn E, Kapur B, Koren G: Iron bioavailability in prenatal multi-
vitamin supplements with separated and combined iron and
calcium.  Journal of Society of Obstetricians and Gynecologists of Canada
2004, 26:806-815.
27. Claxton AJ, Cramer J, Pierce C: A systematic review of the asso-
ciations between dose regimens and medication adherence.
Clin Ther 2001, 23:1296-1310.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2393/8/17/prepub